Pan Hua, Wang Lu, Zhang Xu-Dong, Mai Hai-Xing, Liu Dan, Liu Yin, Guo Shu-Zhong
Institute of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Zhonghua Wai Ke Za Zhi. 2009 Jun 15;47(12):937-40.
To investigate a non-toxic AdCTLA4-Ig-based protocol for non-myeloablative allogeneic hematopoietic cell transplantation to induce donor-specific tolerance to hind limb allografts in rats.
Fully mismatched, 4 to 8 week old Brown Norway (RT1(n)) and Lewis (RT1(1)) rats were used as cell/organ donors and recipients, respectively. Recipients were treated with AdCTLA4-Ig (5 x 10(9) PFU, day -30, 0, 30), standard immunosuppressive therapy (MP: 10 mg x kg(-1) x d(-1), MMF: 20 mg x kg(-1) x d(-1), RAPA: 0.2 mg x kg(-1) x d(-1);day -33 - 100), soon after total body irradiation (3 Gy, day -30) and donor bone marrow (100 x 10(6), day -30) transplantation (BMT). Thirty days after BMT, chimeric animals received hind limb transplantations. And 100 days after hind limb transplantations, immunosuppressive therapy was changed for low-dosed CsA (8 mg x kg(-1) x d(-1), day 100-), until the allografts were rejected.
In Group C, hematopoietic chimerism was (38.8 +/- 10.6)% at day 0, and was stable (29.3 +/- 11.9)% at 330 days post-BMT. There was no graft versus host disease in both Group C and Group D. When the standard immunosuppressive therapy was stopped and changed for low-dosed CsA, chimeric recipients (Lewis, RT1(1)) permanently accepted (> 200 days) donor specific (Brown Norway, RT1(n)) hind limb allografts in Group C, yet rapidly rejected in Group A (8 +/- 2) d, Group B (18 +/- 3) d and in Group C (20 +/- 2) d. Lymphocytes of graft tolerant animals' demonstrated hyporesponsiveness in mixed lymphocyte cultures in a donor-specific manner in Group C. Tolerant graft histology showed no obliterative arteriopathy or chronic rejection.
The AdCTLA4-Ig based conditioning regimen with donor BMT produce stable mixed chimerism and induce donor-specific tolerance to hind limb allografts.
研究一种基于无毒AdCTLA4-Ig的方案用于非清髓性异基因造血细胞移植,以诱导大鼠对后肢同种异体移植物产生供体特异性耐受。
选用完全不匹配的4至8周龄的棕色挪威大鼠(RT1(n))和刘易斯大鼠(RT1(1))分别作为细胞/器官供体和受体。受体接受AdCTLA4-Ig治疗(5×10⁹ PFU,第-30、0、30天)、标准免疫抑制治疗(甲泼尼龙:10 mg·kg⁻¹·d⁻¹,霉酚酸酯:20 mg·kg⁻¹·d⁻¹,雷帕霉素:0.2 mg·kg⁻¹·d⁻¹;第-33至100天),在全身照射(3 Gy,第-30天)和供体骨髓移植(100×10⁶,第-30天)后不久进行。骨髓移植后30天,嵌合动物接受后肢移植。后肢移植后100天,免疫抑制治疗改为低剂量环孢素A(8 mg·kg⁻¹·d⁻¹,第100天起),直至同种异体移植物被排斥。
在C组,第0天时造血嵌合率为(38.8±10.6)%,骨髓移植后330天时稳定在(29.3±11.9)%。C组和D组均未发生移植物抗宿主病。当标准免疫抑制治疗停止并改为低剂量环孢素A时,嵌合受体(刘易斯大鼠,RT1(1))在C组中永久接受(>200天)供体特异性(棕色挪威大鼠,RT1(n))后肢同种异体移植物,但在A组(8±2)天、B组(18±3)天和D组(20±2)天迅速排斥。C组中移植物耐受动物的淋巴细胞在混合淋巴细胞培养中以供体特异性方式表现出低反应性。耐受移植物的组织学检查未显示闭塞性动脉病变或慢性排斥反应。
基于AdCTLA4-Ig的预处理方案联合供体骨髓移植可产生稳定的混合嵌合状态,并诱导对后肢同种异体移植物的供体特异性耐受。